The Microbiome and Cancer Treatment
Overcoming Resistance and Enhancing Efficacy
- 1st Edition - August 1, 2026
- Latest edition
- Editors: Sadhna Aggarwal, Garima Malik, Arun Kumar Singh, Meenakshi Dhanawat
- Language: English
The Microbiome and Cancer Treatment: Overcoming Resistance and Enhancing Efficacy delves into the intricate relationship between the microbiome and cancer treatment, highli… Read more
Sections also address the complex "chicken-or-egg" relationship between microbiome alterations and chemoresistance. A diverse blend of chapters foster interdisciplinary collaboration across fields such as immunology, microbiology, oncology, and pharmacology, promoting holistic approaches to cancer treatment. Readers will benefit by gaining awareness and a better understanding of how the microbiome impacts health, particularly in the context of cancer, leading to more informed health choices.
- Fosters a comprehensive understanding of the microbiome's role in cancer treatment, encouraging collaboration among researchers and healthcare professionals to develop holistic and innovative therapeutic strategies
- Provides practical insights into microbiome-based strategies to overcome chemoresistance, such as the use of probiotics and prebiotics in cancer therapy
- Explores how modulating the gut microbiome can enhance the efficacy of immunotherapies, offering actionable knowledge for the development of personalized and more effective cancer treatments
2. The Microbiome: Its Impact on Cancer Development and Therapeutic Responses
3. Microbiome Dynamics in Cancer Treatment: Impact of Chemotherapy on the Microbiome
4. Microbiome as a Modulator of Immunotherapy: Synergistic Effects of the Microbiome in Immunotherapy
5. Microbiome-Based Strategies to Overcome Chemoresistance: Probiotics and Prebiotics in Cancer Therapy
6. Modulating gut microbiome in cancer immunotherapy: Harnessing microbes to enhance treatment efficacy
7. The Impact of the Microbiome on Resistance to Cancer Treatment with Chemotherapeutic Agents and Immunotherapy
8. Cancer pharmacomicrobiomics: targeting microbiota to optimize cancer therapy outcomes
9. Gut microbiome in modulating immune checkpoint inhibitors
10. Microbiome-based diagnostics and biomarkers: The search for mechanistic connections
11. Modulatory effects of gut microbiome in cancer immunotherapy: A novel paradigm for blockade of immune checkpoint inhibitors
12. Current challenges and Future Prospects for Microbiome Research in Cancer Treatment
- Edition: 1
- Latest edition
- Published: August 1, 2026
- Language: English
SA
Sadhna Aggarwal
GM
Garima Malik
AS
Arun Kumar Singh
MD
Meenakshi Dhanawat
Dr. Meenakshi Dhanawat is an Associate Professor at the Amity Institute of Pharmacy, Amity University Haryana. She earned a Master’s from NIPER Mohali and a PhD from IIT-BHU Varanasi, focusing on medicinal chemistry and CNS drug delivery targeting serotonin receptors. Her research encompasses targeted therapies such as JAK-STAT inhibitors, signaling pathways in health and disease, synthetic and heterocyclic chemistry, nanotechnology-enabled drug delivery, prodrug design, and herbal drug extraction. She has published extensively, holds multiple patents, and contributed to and edited scholarly books and chapters. An active presence at national and international conferences, she has secured competitive grants from major funding agencies. Dr. Dhanawat's work advances pharmaceutical science and education, reflecting a strong commitment to innovation, mentorship, and translational research.